pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), gene alteration target therapy versus bevacizumab based treatment, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.79 [0.38, 1.63]< 10%1 study (1/-)73.9 %NAnot evaluable crucial-
progression or deaths (PFS) 0.23 [0.13, 0.41]< 10%1 study (1/-)100.0 %NAnot evaluable important-
objective responses (ORR) 17.33 [6.66, 45.11]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

TRAE leading to death (grade 5) 0.99 [0.02, 50.39]< 10%1 study (1/-)50.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.